BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11602

524652

INDSWFTLTD

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

IND-SWIFT LIMITED performance

Today’s low

Today’s high

₹ 12.95 ₹ 13.50
₹ 13.01

52 week low

52 week high

₹ 12.46 ₹ 34.70
₹ 13.01

Open Price

₹ 12.99

Prev. Close

₹ 13.17

Volume (Shares)

13004.00

Total traded value

₹ 1.69

Upper Circuit

₹ 14.48

Lower Circuit

₹ 11.85

info

IND-SWIFT LIMITED Share Price Update

As of the latest trading session, IND-SWIFT LIMITED share price is currently at ₹ 13.01, which is down by ₹ -0.15 from its previous closing. Today, the stock has fluctuated between ₹ 12.95 and ₹ 13.50. Over the past year, IND-SWIFT LIMITED has achieved a return of -48.67 %. In the last month alone, the return has been -1.06 %. Read More...

IND-SWIFT LIMITED fundamentals


  • Market cap (Cr)

    70.46

  • P/E Ratio (TTM)

    1.10

  • Beta

    0.63

  • Book Value / share

    -121.56

  • Return on equity

    -12.54%

  • EPS (TTM)

    11.89

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -5.50

info icon alternate text
  • Market cap (Cr)

    70.46

  • P/E Ratio (TTM)

    1.10

  • Beta

    0.46

  • Book Value / share

    -121.56

  • Return on equity

    -12.54%

  • EPS (TTM)

    11.89

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -5.50

info icon alternate text

IND-SWIFT LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 120.13
Operating Expense 128.28
Net Profit -5.50
Net Profit Margin (%) -4.57
Earnings Per Share (EPS) -1.02
EBITDA 9.98
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 136.35
Operating Expense 136.85
Net Profit 4.11
Net Profit Margin (%) 3.01
Earnings Per Share (EPS) 0.76
EBITDA 19.03
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 113.85
Operating Expense 125.53
Net Profit 28.24
Net Profit Margin (%) 24.80
Earnings Per Share (EPS) 5.21
EBITDA 43.15
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 135.23
Operating Expense 142.05
Net Profit 37.54
Net Profit Margin (%) 27.76
Earnings Per Share (EPS) 6.93
EBITDA 61.08
Effective Tax Rate (%) 5.60
Particulars DEC 2023 (Values in Cr)
Revenue 102.56
Operating Expense 120.14
Net Profit -14.97
Net Profit Margin (%) -14.59
Earnings Per Share (EPS) -2.76
EBITDA 7.11
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 502.25
Operating Expense 543.78
Net Profit 14.23
Net Profit Margin (%) 2.83
Earnings Per Share (EPS) 2.63
EBITDA 106.51
Effective Tax Rate (%) 13.54
Particulars MAR 2023 (Values in Cr)
Revenue 410.96
Operating Expense 457.34
Net Profit 26.04
Net Profit Margin (%) 6.33
Earnings Per Share (EPS) 4.81
EBITDA 114.47
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 397.71
Operating Expense 441.60
Net Profit -20.02
Net Profit Margin (%) -5.03
Earnings Per Share (EPS) -3.70
EBITDA 69.63
Effective Tax Rate (%) -2.14
Particulars MAR 2021 (Values in Cr)
Revenue 356.06
Operating Expense 399.57
Net Profit -29.82
Net Profit Margin (%) -8.37
Earnings Per Share (EPS) -5.50
EBITDA 55.39
Effective Tax Rate (%) -1.08
Particulars MAR 2020 (Values in Cr)
Revenue 329.52
Operating Expense 368.46
Net Profit -19.12
Net Profit Margin (%) -5.80
Earnings Per Share (EPS) -3.53
EBITDA 45.61
Effective Tax Rate (%) -14.76
Particulars MAR 2024 (Values in Cr)
Book Value / Share -127.54
ROE % -12.54
ROCE % 3.39
Total Debt to Total Equity 0.00
EBITDA Margin 13.56
Particulars MAR 2023 (Values in Cr)
Book Value / Share -130.10
ROE % 13.19
ROCE % 3.27
Total Debt to Total Equity 0.00
EBITDA Margin 13.05
Particulars MAR 2022 (Values in Cr)
Book Value / Share -132.99
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 17.51
Particulars MAR 2018 (Values in Cr)
Book Value / Share -125.06
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 6.38
Particulars MAR 2017 (Values in Cr)
Book Value / Share -116.26
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -19.35
Particulars MAR 2024 (Values in Cr)
Book Value / Share -127.54
ROE % -12.54
ROCE % 3.39
Total Debt to Total Equity 0.00
EBITDA Margin 13.56
Particulars MAR 2023 (Values in Cr)
Book Value / Share -130.10
ROE % 13.19
ROCE % 3.27
Total Debt to Total Equity 0.00
EBITDA Margin 13.05
Particulars MAR 2022 (Values in Cr)
Book Value / Share -132.99
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 17.51
Particulars MAR 2021 (Values in Cr)
Book Value / Share -128.34
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 15.56
Particulars MAR 2020 (Values in Cr)
Book Value / Share -131.66
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 11.91
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 63.13
Total Assets 654.47
Total Liabilities 654.47
Total Equity -690.82
Share Outstanding 54164653
Price to Book Ratio -0.14
Return on Assets (%) 2.17
Return on Capital (%) 4.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 13.32
Total Assets 649.21
Total Liabilities 649.21
Total Equity -704.69
Share Outstanding 54164653
Price to Book Ratio -0.06
Return on Assets (%) 4.01
Return on Capital (%) 9.04
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 16.18
Total Assets 631.75
Total Liabilities 631.75
Total Equity -720.32
Share Outstanding 54164653
Price to Book Ratio -0.08
Return on Assets (%) -3.16
Return on Capital (%) -6.35
Particulars MAR 2018 (Values in Cr)
Cash & Short Term Investments 3.67
Total Assets 614.75
Total Liabilities 614.75
Total Equity -663.18
Share Outstanding 54164653
Price to Book Ratio -0.06
Return on Assets (%) -8.20
Return on Capital (%) -13.35
Particulars MAR 2017 (Values in Cr)
Cash & Short Term Investments 9.10
Total Assets 659.74
Total Liabilities 659.74
Total Equity -619.85
Share Outstanding 54164653
Price to Book Ratio -0.05
Return on Assets (%) -56.42
Return on Capital (%) -86.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 63.13
Total Assets 654.47
Total Liabilities 654.47
Total Equity -690.82
Share Outstanding 54164653
Price to Book Ratio -0.14
Return on Assets (%) 2.17
Return on Capital (%) 4.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 13.32
Total Assets 649.21
Total Liabilities 649.21
Total Equity -704.69
Share Outstanding 54164653
Price to Book Ratio -0.06
Return on Assets (%) 4.01
Return on Capital (%) 9.04
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 16.18
Total Assets 631.75
Total Liabilities 631.75
Total Equity -720.32
Share Outstanding 54164653
Price to Book Ratio -0.08
Return on Assets (%) -3.16
Return on Capital (%) -6.35
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 28.99
Total Assets 671.57
Total Liabilities 671.57
Total Equity -695.16
Share Outstanding 54164653
Price to Book Ratio -0.04
Return on Assets (%) -4.43
Return on Capital (%) -9.11
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 16.75
Total Assets 601.64
Total Liabilities 601.64
Total Equity -713.11
Share Outstanding 54164653
Price to Book Ratio -0.02
Return on Assets (%) -3.17
Return on Capital (%) -6.34
Particulars MAR 2024 (Values in Cr)
Net Income 16.46
Cash from Operations 15.28
Cash from Investing 76.60
Cash from Financing -42.08
Net change in Cash 49.80
Free Cash Flow 43.77
Particulars MAR 2023 (Values in Cr)
Net Income -34.54
Cash from Operations 73.04
Cash from Investing -29.34
Cash from Financing -46.55
Net change in Cash -2.85
Free Cash Flow 103.87
Particulars MAR 2022 (Values in Cr)
Net Income -20.33
Cash from Operations 50.20
Cash from Investing -18.41
Cash from Financing -44.59
Net change in Cash -12.80
Free Cash Flow 69.77
Particulars MAR 2018 (Values in Cr)
Net Income -50.42
Cash from Operations 7.16
Cash from Investing -6.42
Cash from Financing -6.17
Net change in Cash -5.42
Free Cash Flow 13.32
Particulars MAR 2017 (Values in Cr)
Net Income -371.35
Cash from Operations -1.72
Cash from Investing 4.14
Cash from Financing -10.70
Net change in Cash -8.28
Free Cash Flow 2.72
Particulars MAR 2024 (Values in Cr)
Net Income 16.46
Cash from Operations 15.28
Cash from Investing 76.60
Cash from Financing -42.08
Net change in Cash 49.80
Free Cash Flow 43.77
Particulars MAR 2023 (Values in Cr)
Net Income -34.54
Cash from Operations 73.04
Cash from Investing -29.34
Cash from Financing -46.55
Net change in Cash -2.85
Free Cash Flow 103.87
Particulars MAR 2022 (Values in Cr)
Net Income -20.33
Cash from Operations 50.20
Cash from Investing -18.41
Cash from Financing -44.59
Net change in Cash -12.80
Free Cash Flow 69.77
Particulars MAR 2021 (Values in Cr)
Net Income -28.28
Cash from Operations 83.51
Cash from Investing -16.71
Cash from Financing -54.24
Net change in Cash 12.23
Free Cash Flow 103.73
Particulars MAR 2020 (Values in Cr)
Net Income -19.12
Cash from Operations 34.59
Cash from Investing -11.35
Cash from Financing -26.20
Net change in Cash -2.96
Free Cash Flow 47.23
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

IND-SWIFT LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
13.01 -1.21 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 13.10
  • 26 Days 13.50
  • 10 Days 13.20
  • 50 Days 14.80
  • 12 Days 13.20
  • 100 Days 17.20
  • 20 Days 13.40
  • 200 Days 19.00
13.25 PIVOT

First Support

12.87

First Resistance

13.54

Second Support

12.58

Second Resistance

13.92

Third Support

12.20

Third Resistance

14.21

RSI

43.52

ADX

7.08

MACD

-0.32

Williams % R

-62.90

Commodity Channel Index (CCI)

-9.19

Date

2025-04-30

Week

11256.00

Same Day

10480.00

Month

11256.00

1 Year

0.63

3 Year

0.61

Over 1 Month

-1.06%

down

Over 1 Year

-48.67%

down

Over 3 Months

-27.96%

down

Over 3 Years

4.34%

down

Over 6 Months

-36.78%

down

Over 5 Years

36.45%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

IND-SWIFT LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
44.41%
Promoter Holdings
55.57%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Essix Biosciences Limited 1.7033433E7 (31.45%) Shareholding of Promoter and Promoter Group
S. R. Mehta 2035871.0 (3.76%) Shareholding of Promoter and Promoter Group
Gopal Munjal 1957199.0 (3.61%) Shareholding of Promoter and Promoter Group
V.r. Mehta 1921361.0 (3.55%) Shareholding of Promoter and Promoter Group
Sunita Jain 1812400.0 (3.35%) Shareholding of Promoter and Promoter Group
Late Neera Mehta 1547050.0 (2.86%) Shareholding of Promoter and Promoter Group
Rameshkumar Javerchand Jain 1082500.0 (2.0%) Public Shareholding
Justin Pharmaceuticals Private Limited 860000.0 (1.59%) Public Shareholding
Deepa Ram Kheria 753709.0 (1.39%) Public Shareholding
Gravity Systems Private Limited 750000.0 (1.38%) Public Shareholding
Panchkula Finvest Private Limited 710202.0 (1.31%) Public Shareholding
Ravi Mehta 634470.0 (1.17%) Shareholding of Promoter and Promoter Group
N.r. Munjal 611700.0 (1.13%) Shareholding of Promoter and Promoter Group
Excel Motors Private Limited 586000.0 (1.08%) Public Shareholding
Neeta Munjal 578600.0 (1.07%) Shareholding of Promoter and Promoter Group
Nidhi Munjal 502970.0 (0.93%) Shareholding of Promoter and Promoter Group
Himanshu Jain 495300.0 (0.91%) Shareholding of Promoter and Promoter Group
Meenakshi Mehta 398310.0 (0.74%) Shareholding of Promoter and Promoter Group
Annie Mehta 158630.0 (0.29%) Shareholding of Promoter and Promoter Group
Sahil Munjal 127949.0 (0.24%) Shareholding of Promoter and Promoter Group
Rishav Mehta 111700.0 (0.21%) Shareholding of Promoter and Promoter Group
Saurabh Munjal 51700.0 (0.1%) Shareholding of Promoter and Promoter Group
Ishav Mehta 44200.0 (0.08%) Shareholding of Promoter and Promoter Group
Deepti Munjal 34200.0 (0.06%) Shareholding of Promoter and Promoter Group
Bhanavi Mehta 30300.0 (0.06%) Shareholding of Promoter and Promoter Group
Divya Munjal 15000.0 (0.03%) Shareholding of Promoter and Promoter Group
Daksh Mehta 1000.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

IND-SWIFT LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Sep 2011 0.4 Final 23 Sep 2011 Equity shares
24 Sep 2010 0.4 Final 28 Sep 2010 Equity shares
17 Sep 2009 0.4 Final 21 Sep 2009 Equity shares
19 Sep 2008 0.4 Final 23 Sep 2008 Equity shares
21 Sep 2007 2.0 Final 25 Sep 2007 Equity shares
28 Sep 2006 0.0 Final 30 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 26 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
29 Apr 2005 10.0 2.0 06 May 2005
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Sep 2011 0.4 Final 23 Sep 2011 Equity shares
24 Sep 2010 0.4 Final 28 Sep 2010 Equity shares
17 Sep 2009 0.4 Final 21 Sep 2009 Equity shares
19 Sep 2008 0.4 Final 23 Sep 2008 Equity shares
21 Sep 2007 2.0 Final 25 Sep 2007 Equity shares
28 Sep 2006 0.0 Final 30 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 26 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
29 Apr 2005 10.0 2.0 06 May 2005

IND-SWIFT LIMITED Share Price

Ind-Swift Limited (ISL) is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals.

The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

Ind-Swift Limited was incorporated in June, 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.

In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care.

In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In addition, they launched Institution/Hospital Division.

In the year 2003, the company launched another division by the name Ind-Swift Biosciences. They entered into formulations export to six countries and filed patent in US for Clarithromycin.

In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. The company opened first overseas office in New Jersey, USA

During the year 2004-05, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. They commenced commercial production in their new formulation facility at Jammu, J&K.

During the year 2005-06, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The new product launches included the launch of a unique combination of the Quinoline derivative, anti-diarrheal and anti-bacterial drug that was launched for the first time in India after completion of the successful clinical trials. They also launched the new marketing division namely Institutions & Hospitals division to look after the institutional sales.

During the year, the company commissioned three new state of the art finished dosages facility at; Samba in Jammu & Kashmir; 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh.

During the year 2006-07, the company developed and launched 65 new products and line extension. They launched their product in Kenya and Senegal. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies.

During the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries.

During the year 2007-08, the company's manufacturing unit at Parwanoo was upgraded as per WHO standards. The Global Business Unit (ISL-GBU), commissioned in Derabassi.

In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In December 2007, they launched their new division 'Diagnozis' dealing in medical equipments & devices. The company also launched animal health care, which is absolutely a new concept with outsourced marketing.

Company launched a new marketing division 'NOVA' with special focus on ophthalmology, ENT and Dermatology in 2009-10.

During 2010-11, the Company launched six divisions viz GENERIC, ONCRIT, MEGASWIFT, GYNOSWIFT, Q-DEN and CARDIA SWIFT. Apart from this, it launched new product range in all the new divisions including monopolistic products.

During 2012, the Company diversified into the Dairy Business by launching a new division, which marketed under the brand name 'All Natural'.

In 2021, company established a separate OTC division and launched 2 products via, Stevia and Hangover.

In 2022-23, Company launched many new products such as Linezolid, Ticagrelor, Etoricoxib, and Diclofenac Hot gel and Four Derm ointment etc. Also , Company set up its first wholly owned subsidiary in the Republic of Kenya with the name of Indswift India Limited' in May, 2022. Further, Company also launched new products like Metalazone, Lenalidomide Anhydrous and Methotrexate in the domestic market in 2024.

Parent organization Indian Private
NSE symbol INDSWFTLTD
Founded 1986
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Ind-Swift Ltd?

Answer Field

The share price of Ind-Swift Ltd for NSE is ₹ 13.01 and for BSE is ₹ 13.01.

What is the Market Cap of Ind-Swift Ltd?

Answer Field

The market cap of Ind-Swift Ltd for NSE is ₹ 70.46 Cr. and for BSE is ₹ 70.46 Cr. as of now.

What is the 52 Week High and Low of Ind-Swift Ltd?

Answer Field

The 52 Week High and Low of Ind-Swift Ltd for NSE is ₹ 34.70 and ₹ 12.46 and for BSE is ₹ 34.49 and ₹ 12.51.

How to Buy Ind-Swift Ltd share?

Answer Field

You can trade in Ind-Swift Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Ind-Swift Ltd?

Answer Field

The 1 year returns on the stock has been -48.67%.

What is the Current Share Price of Ind-Swift Ltd?

Answer Field

Ind-Swift Ltd share price is for NSE ₹ 13.01 & for BSE ₹ 13.01 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Ind-Swift Ltd Share?

Answer Field

The market cap of Ind-Swift Ltd for NSE ₹ 70.46 & for BSE ₹ 70.46 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Ind-Swift Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Ind-Swift Ltd share is 1.10.

What is the PB ratio of Ind-Swift Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Ind-Swift Ltd share is -121.56.

How to Buy Ind-Swift Ltd Share?

Answer Field

You can trade in Ind-Swift Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ind-Swift Ltd Share on Bajaj Broking App?

Answer Field

To buy Ind-Swift Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ind-Swift Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|